Nivolumab offers extended overall survival benefit vs docetaxel in patients with advanced non–small-cell lung cancer, according to an analysis with 3 years of follow-up.
A trastuzumab biosimilar known as SB3 showed equivalent efficacy and safety to trastuzumab itself in a phase III trial of women with early HER2-positive breast cancer in the neoadjuvant setting.
Adjuvant radiotherapy after prostatectomy resulted in lower rates of biochemical recurrence, distant metastases, and death compared with surveillance followed by early-salvage radiotherapy in patients with high-risk prostate cancer, according to a new study.
The PAM50 risk of recurrence score can improve the prediction of recurrence at 10 years in postmenopausal patients with HR-positive early breast cancer.
Long-term follow-up of a large phase III study showed that chemohormonal therapy involving docetaxel added to androgen deprivation therapy (ADT) prolongs overall survival over ADT alone in metastatic hormone-sensitive prostate cancer patients with high-volume disease.
Adding palbociclib to letrozole offers similar health-related quality of life and better pain scores in postmenopausal women with estrogen receptor–positive/HER2-negative metastatic breast cancer, compared to letrozole alone, according to an analysis of the PALOMA-2 trial.
A combined approach targeting ER, HER2, and RB1 yielded promising results in terms of Ki-67 expression in women with HER2-positive, ER-positive breast cancer.
A comparison of margin classification systems revealed some differences in their ability to determine local recurrence risk for soft-tissue sarcoma.
Adding bevacizumab maintenance therapy failed to improve outcomes compared with no treatment when administered during chemotherapy-free intervals to patients with metastatic colorectal cancer after induction chemotherapy.
No difference was found in pathologic complete response rates between neoadjuvant paclitaxel and nab-paclitaxel in women with ERBB2/HER2-negative breast cancer.